Retrieved on:
Wednesday, April 24, 2024
Software,
Architecture,
Hardware,
Electronic Design Automation,
Technology,
Other Construction & Property,
Residential Building & Real Estate,
Commercial Building & Real Estate,
Construction & Property,
Urban Planning,
Building Systems,
Other Technology,
Interior Design,
Orion Corporation,
Leo,
Partnership,
History,
Orion,
Multimedia,
Growth Orion Group (“Orion”), a commercial and industrial field services company backed by Alpine Investors (“Alpine”), announced today that it has partnered with Academy Locksmith (“Academy”).
Key Points:
- Orion Group (“Orion”), a commercial and industrial field services company backed by Alpine Investors (“Alpine”), announced today that it has partnered with Academy Locksmith (“Academy”).
- Academy provides mechanical and electronic locksmithing, door, and other access control solutions to multi-site commercial customers throughout the country.
- Orion is building a national facilities maintenance business by partnering with exceptional founder-owned facility services businesses and supplying the resources needed to fuel their next chapter of growth.
- Academy joins Orion’s facilities maintenance service provider network, Leo Facilities Maintenance (“Leo FM”), as its eighth partnership since its founding in 2022.
Retrieved on:
Wednesday, April 10, 2024
Health,
Clinical Trials,
Research,
Pharmaceutical,
Science,
Biotechnology,
Slate,
Glomerulonephritis,
FASN,
Lazard,
Lupus nephritis,
Kidney,
Immunotherapy,
BAFF,
Centerview Partners,
Immunoglobulin A,
Autoimmune disease,
Hart–Scott–Rodino Antitrust Improvements Act,
Patient,
Multimedia,
Vertex Pharmaceuticals,
Pharmaceutical industry Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
Key Points:
- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
- The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
- A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
- For Alpine, Centerview Partners is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.
Retrieved on:
Wednesday, April 10, 2024
Research,
Infectious Diseases,
Hospitals,
Clinical Trials,
Other Health,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Science,
Slate,
Glomerulonephritis,
FASN,
Lazard,
Lupus nephritis,
Kidney,
Immunotherapy,
BAFF,
Centerview Partners,
Immunoglobulin A,
Autoimmune disease,
Hart–Scott–Rodino Antitrust Improvements Act,
Patient,
Vertex Pharmaceuticals,
Pharmaceutical industry Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
Key Points:
- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash.
- The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close later this quarter.
- A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock.
- For Alpine, Centerview Partners is acting as exclusive financial advisor and Fenwick & West LLP as legal counsel.
Retrieved on:
Thursday, February 29, 2024
Oncology,
Health,
FDA,
Other Science,
Science,
Pharmaceutical,
Biotechnology,
Acalabrutinib,
BTK,
Progression-free survival,
Hematology,
Physician,
Odds ratio,
CLL,
BGNE,
Safety,
University,
COVID-19,
Mayo Clinic,
Chronic lymphocytic leukemia,
University of Washington,
Associate,
Patient,
Survival,
Rituximab,
Clutch (eggs),
ASCEND,
Pharmaceutical industry The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival.
Key Points:
- The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival.
- These data will be presented during the 28th Annual International Congress on Hematologic Malignancies® in Miami from February 29 - March 3.
- “Head-to-head randomized clinical trials are the gold standard when it comes to evaluating the potential impact of individual treatments for patients.
- The global BRUKINSA development program includes more than 5,000 subjects enrolled to date in 29 countries and regions.
Retrieved on:
Wednesday, August 2, 2023
AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cotton Creek Capital (“Cotton Creek”) is pleased to announce a partnership with the management of Alpine Communication, LLC (“Alpine”) to form Alpine Infrastructure Partners, LLC (“Alpine Infrastructure”).
Key Points:
- AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cotton Creek Capital (“Cotton Creek”) is pleased to announce a partnership with the management of Alpine Communication, LLC (“Alpine”) to form Alpine Infrastructure Partners, LLC (“Alpine Infrastructure”).
- Alpine is a leading provider of critical field and administrative services to utility and telecommunications customers throughout the US.
- Headquartered in Ormond Beach, Florida, Alpine specializes in a variety of field services and outsourced business processes, including permit administration, pole attachment analysis and inspections, joint use audits, and drafting services.
- We anticipate accelerated growth alongside the Cotton Creek team given their extensive experience with telecommunications and power utilities customers,” said Founder and Executive Chairman of Alpine, Mitch Veynovich.
Interior Design,
Architecture,
Commercial Building & Real Estate,
Construction & Property,
Building Systems,
REIT,
Social responsibility,
Maintenance,
Growth,
Partnership,
Orion Corporation,
Multimedia,
Industrial design Orion Group (“Orion”), a commercial and industrial field services company backed by Alpine Investors (“Alpine”), today announced that it has partnered with CS Hudson – a leading interior services facilities maintenance company based in Hauppauge, NY.
Key Points:
- Orion Group (“Orion”), a commercial and industrial field services company backed by Alpine Investors (“Alpine”), today announced that it has partnered with CS Hudson – a leading interior services facilities maintenance company based in Hauppauge, NY.
- View the full release here: https://www.businesswire.com/news/home/20230707691687/en/
As Orion’s sixth investment in the facilities maintenance industry, the partnership with CS Hudson stems from Orion’s ongoing mission to develop a national facilities maintenance business by partnering with exceptional founder-owned facility service businesses and providing resources to fuel their next chapters of growth.
- “CS Hudson has an excellent reputation as a trusted advisor on its customers’ toughest facilities maintenance challenges and for timely, dependable service.
- It offers a comprehensive range of 40+ reactive and scheduled facility maintenance services, including handyman, plumbing, electrical, remediation, and other interior facilities services across the country.
Retrieved on:
Tuesday, February 28, 2023
Tier One Entertainment,
Renault,
Non-fungible token,
Big,
Formula,
QAN,
Partnership,
F1,
Esports,
Hope,
Kappa,
TEAM,
Formula One Esports Series,
Language,
The Co Founder,
Cryptocurrency,
Video game,
Alpine,
Enstone ALPINE ESPORTS SIGNS QANPLATFORM AS ITS OFFICIAL BLOCKCHAIN PARTNER TO SUPPORT FAN ENGAGEMENT, TEAM PERFORMANCE AND OPERATIONS
Key Points:
- ALPINE ESPORTS SIGNS QANPLATFORM AS ITS OFFICIAL BLOCKCHAIN PARTNER TO SUPPORT FAN ENGAGEMENT, TEAM PERFORMANCE AND OPERATIONS
The issuer is solely responsible for the content of this announcement.
- For Alpine Esports the partnership will aid the team's fan engagement strategy and allow them to create practical use cases that will support internal operations.
- QANplatform will become the Official Blockchain Partner of Alpine Esports where besides the use cases, QANplatform will take pride of place on the new F1 Esports team jersey and esport cars next to other partners like Binance, Kappa, and Shamir.
- Alpine Esports invested in Web3 activations in 2022, playing a pivotal role in their fan engagement strategy with the launch of the Alpine Esports Series which saw them offer $100k worth Alpine Fan Tokens.
Retrieved on:
Thursday, January 19, 2023
Oncology,
Health,
FDA,
Clinical Trials,
Pharmaceutical,
Biotechnology,
PFS,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Rituximab,
CLL,
SSE,
SLL,
SEQUOIA,
Food,
Chronic lymphocytic leukemia,
Patient,
Multimedia,
Lymphocytosis,
Hematology,
Progression-free survival,
Pharmaceutical industry,
BeiGene BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Key Points:
- BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- This press release features multimedia.
- With a median follow-up of 29.6 months, BRUKINSA demonstrated superior PFS compared with ibrutinib in patients with R/R CLL (HR: 0.65 [95% CI, 0.49-0.86] P=.0024, for both investigator and IRC).
- I’m pleased that the approval of zanubrutinib provides a new BTKi option for people with CLL/SLL, with demonstrated efficacy as well as being very well tolerated long-term,” said Brian Koffman, M.D., Chief Medical Officer and Executive Vice-President at CLL Society.
Retrieved on:
Tuesday, December 13, 2022
In this final analysis, BRUKINSA achieved superior PFS over ibrutinib (HR: 0.65 [95% CI, 0.49-0.86] p=0.0024, for both Independent Review Committee [IRC] and investigator).
Key Points:
- In this final analysis, BRUKINSA achieved superior PFS over ibrutinib (HR: 0.65 [95% CI, 0.49-0.86] p=0.0024, for both Independent Review Committee [IRC] and investigator).
- At 24 months, the investigator-assessed PFS rates were 78.4% for BRUKINSA compared to 65.9% with ibrutinib.
- BRUKINSA also demonstrated higher overall response rate (ORR), with a response rate of 80.4% versus 72.9% (two-sided p=0.0264), as assessed by IRC.
- Cancer Stat Facts: Leukemia Chronic Lymphocytic Leukemia (CLL).
Retrieved on:
Wednesday, October 12, 2022
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Oncology,
U.S. Securities and Exchange Commission,
BTK,
Disease,
PFS,
Therapy,
CLL,
Review,
New Drug Application,
Lymphocytosis,
NASDAQ,
Patient,
Hematology,
Incidence,
Twitter,
HIV disease progression rates,
Tissue,
Technology,
Private Securities Litigation Reform Act,
Goal,
IRC,
Marketing,
Flutter,
Pharmacokinetics,
Toxicity,
SSE,
SLL,
Adult,
Congress,
Safety,
Atrial fibrillation,
Pharmacyclics,
Intellectual property,
Progression-free survival,
Janssen Biotech,
FDA,
COVID-19,
Lymphoid leukemia,
Half-life,
Classification,
View,
Pharmaceutical industry,
Medical device,
ORR,
BeiGene,
EU BRUKINSA was generally well tolerated; safety findings at the final PFS analysis were consistent with prior reports.
Key Points:
- BRUKINSA was generally well tolerated; safety findings at the final PFS analysis were consistent with prior reports.
- With this final PFS analysis, BRUKINSA has achieved superior progression free survival, as well as superiority in overall response rate versus ibrutinib, said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene.
- ALPINE is a randomized, global Phase 3 trial (NCT03734016) comparing BRUKINSA against ibrutinib in previously treated patients with relapsed or refractory CLL or SLL.
- In April 2022, BeiGene announced results from the final response analysis showing BRUKINSA demonstrated superiority versus ibrutinib in ORR as assessed by an IRC.
